Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

Saeed Rafii, MD, PhD
Published: Friday, Sep 02, 2016



Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses investigational immunotherapy approaches for the treatment of patients with bladder cancer.

Rafii envisions that there will be more clinical trials exploring anti–PD-1 agents in this field. This includes combination studies of PD-1 and CTLA-4 inhibitors, as well as basket trials studying combinations of immunotherapy with olaparib (Lynparza) and EGFR inhibitors. Another ongoing trial is looking at durvalumab compared with chemotherapy.

Results of such studies, which will be announced over the next few years, will explain whether immunotherapy will become a frontline choice and compete with chemotherapy, or could be administered as part of a combination regimen.


Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses investigational immunotherapy approaches for the treatment of patients with bladder cancer.

Rafii envisions that there will be more clinical trials exploring anti–PD-1 agents in this field. This includes combination studies of PD-1 and CTLA-4 inhibitors, as well as basket trials studying combinations of immunotherapy with olaparib (Lynparza) and EGFR inhibitors. Another ongoing trial is looking at durvalumab compared with chemotherapy.

Results of such studies, which will be announced over the next few years, will explain whether immunotherapy will become a frontline choice and compete with chemotherapy, or could be administered as part of a combination regimen.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x